Abstract:Background Endogenous aldehyde damages DNA and potentiates an ageing phenotype. The aldehyde dehydrogenase 2 (ALDH2) rs671 polymorphism has a prevalence of 30%-50% in Asian populations. In this study, we aimed to analyze risk factors contributing to the development of heart failure with preserved ejection fraction (HFpEF) along with the genetic exposure in Chinese patients hospitalized with cardiovascular diseases (CVD). Methods From July 2017 to October 2018, a total of 770 consecutive Chinese patients with normal left ventricular ejection fractions (LVEF) and established CVD (hypertension, coronary heart diseases, or diabetes) were enrolled in this prospective cross-sectional study. HFpEF was defined by the presence of at least one of symptom (dyspnoea and fatigue) or sign (rales and ankle swelling) related to heart failure; N-terminal pro-B-Type natriuretic peptide (NT pro-BNP >= 280 pg/mL); LVEF >= 50%; and at least one criterion related to elevated ventricular filling pressure or diastolic dysfunction (left atrial diameter > 40 mm, E/E' >= 13, E'/A' < 1 or concurrent atrial fibrillation). Logistic regression was performed to yield adjusted odds ratios (ORs) for HFpEF incidence associated with traditional and/or genetic exposures. Results Finally, among 770 patients with CVD, 92 (11.9%) patients were classified into the HFpEF group according to the diagnostic criteria. The mean age of the participants was 67 +/- 12 years, and 278 (36.1%) patients were females. A total of 303 (39.4%) patients were ALDH2*2 variant carriers. In the univariate analysis, eight exposures were found to be associated with HFpEF: atrial fibrillation, ALDH2*2 variants, hypertension, age, anaemia, smoking, alcohol consumption and sex. Multivariable logistic regression showed that 4 'A' variables (atrial fibrillation, ALDH2*2 variants, age and anaemia) were significantly associated with an increased risk of HFpEF. Atrial fibrillation was associated with a 3.8-fold increased HFpEF risk (95% CI: 2.21-6.61, P < 0.001), and the other three exposures associated with increased HFpEF risk were the ALDH2*2 variant (OR = 2.41, 95% CI: 1.49-3.87, P < 0.001), age (OR = 2.14, 95% CI: 1.27-3.60, P = 0.004), and anaemia (OR = 1.79, 95% CI: 1.05-3.03, P = 0.032). These four variables predicted HFpEF incidence in Chinese CVD patients (C-statistic = 0.745, 95% CI: 0.691-0.800, P < 0.001). Conclusions 4 A traits (atrial fibrillation, ALDH2*2 variants, age and anaemia) were associated with an increased risk of HFpEF in Chinese CVD patients. Our results provide potential clues to the aetiology, pathophysiology and therapeutic targets of HFpEF.

Targeting Acetaldehyde Dehydrogenase 2 (ALDH2) in Heart Failure-Recent Insights and Perspectives.

Aldehyde dehydrogenase 2 and arrhythmogenesis

Characterization of the Molecular Mechanisms Underlying Increased Ischemic Damage in the Aldehyde Dehydrogenase 2 Genetic Polymorphism Using a Human Induced Pluripotent Stem Cell Model System.

The role of aldehyde dehydrogenase 2 in cardiovascular disease

Advances in Factors Affecting ALDH2 Activity and its Mechanisms

ALDH2 Rs671 Polymorphism and the Risk of Heart Failure with Preserved Ejection Fraction (hfpef) in Patients with Cardiovascular Diseases

ALDH2 in alcoholic heart diseases: molecular mechanism and clinical implications.

Heart failure: advanced development in genetics and epigenetics.

Aldehyde Dehydrogenase 2-Associated Metabolic Abnormalities and Cardiovascular Diseases: Current Status, Underlying Mechanisms, and Clinical Recommendations

Risks of Incident Heart Failure with Preserved Ejection Fraction in Chinese Patients Hospitalized for Cardiovascular Diseases.

Aldehyde Dehydrogenase-2 Roles in Ischemic Cardiovascular Disease.

Aldehyde Dehydrogenase 2 (ALDH2) rs671 Polymorphism is a Predictor of Pulmonary Hypertension Due to Left Heart Disease

ALDH2 polymorphism and myocardial infarction: From alcohol metabolism to redox regulation

Contribution of Aldh2 Polymorphism to Alcoholism-Associated Hypertension

Aldehyde Dehydrogenase 2 and Heart Failure.

Aldehyde dehydrogenase 2 preserves kidney function by countering acrolein-induced metabolic and mitochondrial dysfunction

The ALDH2 gene rs671 polymorphism is associated with cardiometabolic risk factors in East Asian population: an updated meta-analysis

Abstract 19679: Mitochondrial Aldehyde Dehydrogenase 2 (ALDH2) Ameliorates Angiotensin II-Induced Cardiac Remodeling and Myocardial Dysfunction through Inhibition of Mitochondrial Oxidative Stress and Induction of Autophagy

Abstract 12754: Association of Aldh2 Gene Polymorphism with Cardiac Function Insufficiency after Myocardial Infarction in Chinese Han Population

Glu504Lys Single Nucleotide Polymorphism of Aldehyde Dehydrogenase 2 Gene and the Risk of Human Diseases

Aldehyde Dehydrogenase 2 (ALDH2) and Aging: Is There a Sensible Link?